Approval of ‘Invega Trinza,’ Janssen’s schizophrenia, is approaching

A schizophrenia therapy to administer 4 times a year is soon to be commercialized.

According to the industry concerned on the 30^th, a Janssen Korea’s long-acting injection which was applied for approval at the end of the last year, ‘Invega Trinza,’ is expected to acquire approval from the Ministry of Food and Drug Safety(MFDS) next month.

The therapy, an upgraded version of ‘Invega Sustenna...